GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (OTCPK:IPCIF) » Definitions » Shares Outstanding (EOP)

IntelliPharmaCeutics International (IntelliPharmaCeutics International) Shares Outstanding (EOP) : 33.09 Mil (As of Aug. 2023)


View and export this data going back to 1996. Start your Free Trial

What is IntelliPharmaCeutics International Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. IntelliPharmaCeutics International's shares outstanding for the quarter that ended in Aug. 2023 was 33.09 Mil.

IntelliPharmaCeutics International's quarterly shares outstanding stayed the same from May. 2023 (33.09 Mil) to Aug. 2023 (33.09 Mil).

IntelliPharmaCeutics International's annual shares outstanding stayed the same from Nov. 2021 (33.09 Mil) to Nov. 2022 (33.09 Mil).


IntelliPharmaCeutics International Shares Outstanding (EOP) Historical Data

The historical data trend for IntelliPharmaCeutics International's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International Shares Outstanding (EOP) Chart

IntelliPharmaCeutics International Annual Data
Trend Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.25 22.09 23.68 33.09 33.09

IntelliPharmaCeutics International Quarterly Data
Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.09 33.09 33.09 33.09 33.09

Competitive Comparison of IntelliPharmaCeutics International's Shares Outstanding (EOP)

For the Biotechnology subindustry, IntelliPharmaCeutics International's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IntelliPharmaCeutics International's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's Shares Outstanding (EOP) falls into.



IntelliPharmaCeutics International Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


IntelliPharmaCeutics International  (OTCPK:IPCIF) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


IntelliPharmaCeutics International Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


IntelliPharmaCeutics International (IntelliPharmaCeutics International) Business Description

Traded in Other Exchanges
Address
30 Worcester Road, Toronto, ON, CAN, M9W 5X2
IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.